Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patient-rated ease of use and functional reliability of an electronic autoinjector for self-injection of subcutaneous interferon beta-1a for relapsing multiple sclerosis.
Singer B, Wray S, Miller T, Cascione M, Gupta A, Pardo G, Watsky E, Hayward B, Mercer B, Dangond F. Singer B, et al. Among authors: dangond f. Mult Scler Relat Disord. 2012 Apr;1(2):87-94. doi: 10.1016/j.msard.2011.11.002. Epub 2012 Jan 20. Mult Scler Relat Disord. 2012. PMID: 25876936
Rebif(®) Quality of Life (RebiQoL): A randomized, multicenter, Phase IIIb study evaluating quality-of-life measures in patients receiving the serum-free formulation of subcutaneous interferon beta-1a for the treatment of relapsing forms of multiple sclerosis.
Bandari D, Wynn D, Miller T, Singer B, Wray S, Bennett R, Hayward B, Dangond F; RebiQoL Study Group. Bandari D, et al. Among authors: dangond f. Mult Scler Relat Disord. 2013 Jan;2(1):45-56. doi: 10.1016/j.msard.2012.07.005. Epub 2012 Sep 25. Mult Scler Relat Disord. 2013. PMID: 25877454
Results from the single-use autoinjector for self-administration of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis (MOSAIC) study.
Wray S, Armstrong R, Herrman C, Calkwood J, Cascione M, Watsky E, Hayward B, Mercer B, Dangond F. Wray S, et al. Among authors: dangond f. Expert Opin Drug Deliv. 2011 Dec;8(12):1543-53. doi: 10.1517/17425247.2011.628656. Epub 2011 Oct 27. Expert Opin Drug Deliv. 2011. PMID: 22032264 Clinical Trial.
Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study.
Singer B, Bandari D, Cascione M, LaGanke C, Huddlestone J, Bennett R, Dangond F; REFORMS Study Group. Singer B, et al. Among authors: dangond f. BMC Neurol. 2012 Dec 6;12:154. doi: 10.1186/1471-2377-12-154. BMC Neurol. 2012. PMID: 23216674 Free PMC article. Clinical Trial.
Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing-remitting multiple sclerosis over 24 weeks of therapy with subcutaneous interferon beta-1a three times weekly.
Dwyer MG, Zivadinov R, Markovic-Plese S, Bergsland N, Heininen-Brown M, Carl E, Kennedy C, Weinstock-Guttman B, Hayward B, Dangond F. Dwyer MG, et al. Among authors: dangond f. J Neuroimmunol. 2015 Apr 15;281:44-50. doi: 10.1016/j.jneuroim.2015.03.002. Epub 2015 Mar 5. J Neuroimmunol. 2015. PMID: 25867467 Free article. Clinical Trial.
Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study.
Zivadinov R, Dwyer MG, Markovic-Plese S, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Hayward B, Dangond F, Weinstock-Guttman B. Zivadinov R, et al. Among authors: dangond f. PLoS One. 2014 Mar 13;9(3):e91098. doi: 10.1371/journal.pone.0091098. eCollection 2014. PLoS One. 2014. PMID: 24625687 Free PMC article.
80 results